Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?

NEW YORK (TheStreet) -- Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash, according to Reuters.

Santaris develops drugs to fight liver cancer, head and neck cancer, and against metabolic and infectious diseases.

It is partly owned by Danish venture capital firm Sunstone, which earlier this year considered a U.S. listing for the company, Reuters said. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of Roche Holding are down -0.79% to $35.98.

RHHBY ChartRHHBY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Could Spotify Be Next on Amazon's Wish List?

Could Spotify Be Next on Amazon's Wish List?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Video: This Is One Way Millennials Are Destroying Their Financial Future

Video: This Is One Way Millennials Are Destroying Their Financial Future